EMvision Medical Devices Ltd (ASX: EMV) Share Price and News
Price
–
Movement
– ( )
(20 mins delayed)
52 Week Range
– - –
1 Year Return
EMvision Medical Devices Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$148.80 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
85.52 million
Earnings per share
-0.074
Dividend per share
N/A
Year To Date Return
-8.18%
Earnings Yield
N/A
Franking
-
Share Price
–
Day Change
– ( )
52 Week Range
– - –
Yesterday's Close
–
Today's Open
–
Days Range
– - –
Volume
–
Avg. Volume (1 month)
–
Turnover
–
EMvision Medical Devices Ltd (ASX: EMV)
Latest News
Earnings Results
3 ASX shares soaring on earnings updates
Healthcare Shares
EMvision share price rockets 11% on $5 million pay day
Technology Shares
Here's why the EMvision share price surged 8% on Wednesday
Healthcare Shares
EMvision (ASX:EMV) share price slides 5% following FDA update
Share Gainers
EMvision (ASX:EMV) share price leaps 14% on product update
Healthcare Shares
The EMvision (ASX:EMV) share price jumped today. Here's why
Healthcare Shares
Why is the EMvision (ASX:EMV) share price surging 12% this week?
Share Market News
Why the EMvision (ASX: EMV) share price closed 13% higher today
Share Market News
Why the EMvision (ASX:EMV) share price is going nowhere
Share Market News
Here's why the EMvision (ASX:EMV) share price is up 9% this week
Share Market News
EMvision (ASX:EMV) share price falling despite positive results
EMV ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|
About EMvision Medical Devices Ltd
EMvision Medical Devices Ltd is an Australian medical device company. The company is focused on the research and development and commercialisation of neurodiagnostic technology for stroke diagnosis and monitoring, as well as other medical imaging needs. Its focus is portable, cost effective and non-invasive brain scanners, including a bedside device (emu) and an ultra-light weight first responder pre-hospital device.
EMV Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 20 Jun 2025 | $1.74 | $-0.02 | -1.14% | 12,847 | $1.75 | $1.78 | $1.74 |
| 19 Jun 2025 | $1.76 | $-0.04 | -2.22% | 30,666 | $1.78 | $1.80 | $1.76 |
| 18 Jun 2025 | $1.80 | $0.01 | 0.56% | 34,833 | $1.78 | $1.83 | $1.76 |
| 17 Jun 2025 | $1.80 | $-0.01 | -0.56% | 33,660 | $1.80 | $1.81 | $1.75 |
| 16 Jun 2025 | $1.80 | $0.01 | 0.56% | 43,157 | $1.82 | $1.85 | $1.80 |
| 13 Jun 2025 | $1.79 | $-0.04 | -2.18% | 72,230 | $1.85 | $1.85 | $1.72 |
| 12 Jun 2025 | $1.84 | $0.07 | 3.95% | 56,977 | $1.82 | $1.86 | $1.76 |
| 11 Jun 2025 | $1.77 | $-0.01 | -0.56% | 14,182 | $1.79 | $1.79 | $1.77 |
| 10 Jun 2025 | $1.78 | $0.01 | 0.56% | 36,776 | $1.78 | $1.83 | $1.75 |
| 06 Jun 2025 | $1.78 | $0.07 | 4.09% | 5,541 | $1.72 | $1.78 | $1.72 |
| 05 Jun 2025 | $1.71 | $0.01 | 0.59% | 20,740 | $1.71 | $1.77 | $1.71 |
| 04 Jun 2025 | $1.70 | $-0.07 | -3.97% | 5,088 | $1.76 | $1.78 | $1.70 |
| 03 Jun 2025 | $1.77 | $0.12 | 7.29% | 22,312 | $1.70 | $1.78 | $1.66 |
| 02 Jun 2025 | $1.65 | $-0.05 | -2.94% | 66,081 | $1.70 | $1.70 | $1.65 |
| 30 May 2025 | $1.70 | $-0.01 | -0.58% | 14,354 | $1.71 | $1.71 | $1.70 |
| 29 May 2025 | $1.71 | $-0.04 | -2.29% | 20,723 | $1.74 | $1.75 | $1.71 |
| 28 May 2025 | $1.75 | $-0.03 | -1.69% | 38,607 | $1.79 | $1.85 | $1.73 |
| 27 May 2025 | $1.78 | $0.00 | 0.00% | 20,488 | $1.78 | $1.78 | $1.73 |
| 26 May 2025 | $1.78 | $0.07 | 4.09% | 23,105 | $1.77 | $1.78 | $1.75 |
| 23 May 2025 | $1.71 | $-0.03 | -1.72% | 22,415 | $1.75 | $1.75 | $1.70 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 20 Nov 2024 | Patryk Kania | Issued | 200,000 | $386,000 |
Issue of options.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Phillip James Dubois | Non-Executive Director | Sep 2020 |
Dr Dubois is an independent Non-executive Director. He is a neuroradiologist and nuclear imaging specialist, and up until recently a Non-Executive Director of Sonic Healthcare Limited, former CEO of their imaging division and served as Executive Director from 2001 to 2020.
|
| Mr Anthony (Tony) Keane | Non-Executive Director | Jun 2018 |
Mr Keane is an experienced business and finance executive and holds a number of independent non-executive director and advisory board roles. Mr Keane also undertakes finance advisory and consultancy assignments for various business clients and previously held numerous roles with a major trading bank principally in business, corporate and institutional banking. He is the Chair of Risk Committee.
|
| Mr John Keep | Non-Executive ChairmanNon-Executive Director | Mar 2018 |
Mr Keep has public company board and senior management experience in the healthcare and hospitality sectors including both medical diagnostic companies and start up enterprises. He is a member of the Risk Committee.
|
| Mr Scott Kirkland | Co-founderExecutive DirectorChief Executive OfficerManaging Director | Jul 2017 |
Mr Kirkland has held several senior sales and marketing positions, including Head of Client Sales at Quantcast, a US-based AI technology company, prior to establishing EMVision as a leader in innovative neurodiagnostic technology.
|
| Mr Patryk Kania | Non-Executive Director | Mar 2024 |
Mr Kania is a medical device executive with over 20 years of commercialisation and leadership experience in medical devices, pharma and health technologies working across the US, Europe and APAC, within sales and marketing management, and general management roles.
|
| Ms Carmel Monaghan | Non-Executive Director | Jun 2025 |
Ms Monaghan is a healthcare leader being the Chief Executive Officer of Ramsay Healthcare Australia (ASX:RHC) since 2020. Ms Monaghan has worked across hospital, corporate and global positions at Ramsay for three decades. Prior to her appointment as CEO of Ramsay Australia, Ms Monaghan was the Group Chief of Staff of Ramsay global operations, gaining experience and a comprehensive understanding of health care operations and strategy both in Australia and overseas. Ms Monaghan also served as the Group Head of Marketing and Public Affairs, driving marketing, brand and communications strategy.
|
| Ms Emma Waldon | Company Secretary |
-
|
|
| Emma Waldon | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Keysight Technologies Inc | 7,454,231 | 8.73% |
| Mr Scott Philip Kirkland | 3,861,987 | 4.52% |
| Citicorp Nominees Pty Limited | 3,623,186 | 4.24% |
| Mr Ryan Michael Laws | 3,147,250 | 3.68% |
| BNP Paribas Nominees Pty Ltd <HUB24 Custodial Serv Ltd> | 1,528,587 | 1.79% |
| Mr Paul Raymond Brown & Mrs Angelique Susan Brown <Brown Family A/C> | 1,434,500 | 1.68% |
| J P Morgan Nominees Australia Pty Limited | 1,293,793 | 1.51% |
| Jm Starcevich Investments Pty Ltd | 1,230,000 | 1.44% |
| Uniquest Pty Limited | 1,200,000 | 1.40% |
| Busso Holdings Pty Ltd <Bew A/C> | 1,160,000 | 1.36% |
| Glensburg Pty Ltd <Tyto Corp Pension Fund A/C> | 1,112,000 | 1.30% |
| Walsh Prestige Pty Ltd <Walsh Family A/C> | 1,050,000 | 1.23% |
| Dr Stuart Crozier | 1,044,937 | 1.22% |
| Mr Vincent Michael O'Sullivan <O'Sullivan A/C> | 1,010,101 | 1.18% |
| Mr Martin Kolev | 1,000,000 | 1.17% |
| Oofy Prosser Pty Ltd <Drones Family A/C> | 855,000 | 1.00% |
| Mr Kong Pak Lim | 810,500 | 0.95% |
| Wakil Family Group Pty Ltd <Ron Ton Fashions P/L Rp A/C> | 797,519 | 0.93% |
| Hillridge Pty Ltd | 753,165 | 0.88% |
| Pit2 Co Pty Ltd <Power Investment 2 A/C> | 741,298 | 0.87% |